These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38465615)

  • 1. The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States.
    O'Callaghan L; Chertavian E; Johnson SJ; Ferries E; Deligiannidis KM
    J Med Econ; 2024; 27(1):492-505. PubMed ID: 38465615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Brexanolone Versus Selective Serotonin Reuptake Inhibitors for the Treatment of Postpartum Depression in the United States.
    Eldar-Lissai A; Cohen JT; Meltzer-Brody S; Gerbasi ME; Chertavian E; Hodgkins P; Bond JC; Johnson SJ
    J Manag Care Spec Pharm; 2020 May; 26(5):627-638. PubMed ID: 32191592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression.
    Meltzer-Brody S; Gerbasi ME; Mak C; Toubouti Y; Smith S; Roskell N; Tan R; Chen SS; Deligiannidis KM
    J Med Econ; 2024; 27(1):582-595. PubMed ID: 38523596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression.
    Cooper MC; Kilvert HS; Hodgkins P; Roskell NS; Eldar-Lissai A
    CNS Drugs; 2019 Oct; 33(10):1039-1052. PubMed ID: 31642037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression.
    Barnes KN; Vogl CM; Nelson LA
    Ann Pharmacother; 2024 Jul; 58(7):728-734. PubMed ID: 37876133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA
    Sharma R; Bansal P; Saini L; Sharma N; Dhingra R
    Pharmacol Biochem Behav; 2024 May; 238():173734. PubMed ID: 38387651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon.
    Nashwan AJ; Rehan ST; Imran L; Abbas SG; Khan SF
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jun; 132():110983. PubMed ID: 38412941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
    Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
    Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings.
    Lynch FL; Dickerson JF; Clarke G; Vitiello B; Porta G; Wagner KD; Emslie G; Asarnow JR; Keller MB; Birmaher B; Ryan ND; Kennard B; Mayes T; DeBar L; McCracken JT; Strober M; Suddath RL; Spirito A; Onorato M; Zelazny J; Iyengar S; Brent D
    Arch Gen Psychiatry; 2011 Mar; 68(3):253-62. PubMed ID: 21383263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study.
    Kendrick T; Chatwin J; Dowrick C; Tylee A; Morriss R; Peveler R; Leese M; McCrone P; Harris T; Moore M; Byng R; Brown G; Barthel S; Mander H; Ring A; Kelly V; Wallace V; Gabbay M; Craig T; Mann A
    Health Technol Assess; 2009 Apr; 13(22):iii-iv, ix-xi, 1-159. PubMed ID: 19401066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.
    Clayton AH; Suthoff E; Jain R; Kosinski M; Fridman M; Deligiannidis KM; Meltzer-Brody S; Chen SY; Gervitz L; Huang MY; Trivedi M; Bonthapally V
    J Affect Disord; 2024 Apr; 351():904-914. PubMed ID: 38325605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
    Sullivan PW; Valuck R; Saseen J; MacFall HM
    CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
    Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
    Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
    JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zuranolone: A Narrative Review of a New Oral Treatment for Postpartum Depression.
    Hitt EM
    Clin Ther; 2024 May; 46(5):433-438. PubMed ID: 38697873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective serotonin reuptake inhibitors (SSRIs) for post-partum depression (PPD): a systematic review of randomized clinical trials.
    De Crescenzo F; Perelli F; Armando M; Vicari S
    J Affect Disord; 2014 Jan; 152-154():39-44. PubMed ID: 24139299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.
    Villacorta R; Hay JW; Messali A
    Pharmacoeconomics; 2013 Sep; 31(9):823-39. PubMed ID: 23975739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.